The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
NCT ID: NCT04358224
Last Updated: 2023-02-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
12 participants
INTERVENTIONAL
2020-09-01
2022-11-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Bacterial Toxins in Human Skin Disease
NCT02910791
Identification of Epidermal Signatures in Patients With Atopic Dermatitis
NCT02680405
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.
NCT02932891
A National Registry For Patients With Hidradenitis Suppurativa
NCT03289585
Prediction of Rituximab Hypersensitivity and Desensitization Treatment
NCT04610242
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
open-label
open-label
Dupilumab Prefilled Syringe
open-label
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dupilumab Prefilled Syringe
open-label
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jonathan A. Bernstein, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan A. Bernstein, MD
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Bernstein
Role: PRINCIPAL_INVESTIGATOR
Bernstein Clinial Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bernstein Clinical Research Center
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R668-AD-1830
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.